These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 34913631)

  • 1. Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization.
    Moll MA; Zwerger D; Grassl KJ; Westreicher W; Neururer SB; Moll CW; Wipper SH; Klocker J
    Int Angiol; 2022 Feb; 41(1):56-62. PubMed ID: 34913631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
    Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
    Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
    Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
    Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Govsyeyev N; Nehler M; Conte MS; Debus S; Chung J; Dorigo W; Gudz I; Krievins D; Mills J; Moll F; Norgren L; Piffaretti G; Powell R; Szalay D; Sillesen H; Wohlauer M; Szarek M; Bauersachs RM; Anand SS; Patel MR; Capell WH; Jaeger N; Hess CN; Muehlhofer E; Haskell LP; Berkowitz SD; Bonaca MP
    J Vasc Surg; 2023 Apr; 77(4):1107-1118.e2. PubMed ID: 36470531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editor's Choice - Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD.
    Aboyans V; Morboeuf O; Grenier B; Jolivel R; Bura-Riviere A
    Eur J Vasc Endovasc Surg; 2024 Jun; 67(6):969-978. PubMed ID: 38316351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
    Bauersachs RM; Szarek M; Brodmann M; Gudz I; Debus ES; Nehler MR; Anand SS; Patel MR; Hess CN; Capell WH; Rogers K; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP;
    J Am Coll Cardiol; 2021 Jul; 78(4):317-326. PubMed ID: 34010631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
    Søgaard M; Nielsen PB; Skjøth F; Larsen TB; Eldrup N
    Eur J Vasc Endovasc Surg; 2022 Feb; 63(2):285-294. PubMed ID: 34924303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
    Hess CN; Baumgartner I; Anand SS; Nehler MR; Patel MR; Debus ES; Szarek M; Capell W; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM; Bonaca MP; Hsia J
    J Am Heart Assoc; 2022 Jun; 11(12):e024655. PubMed ID: 35699170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
    Hess CN; Debus ES; Nehler MR; Anand SS; Patel MR; Szarek M; Capell WH; Hsia J; Beckman JA; Brodmann M; Diaz R; Habertheuer P; Leeper NJ; Powell RJ; Sillesen H; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM; Bonaca MP
    Circulation; 2021 Dec; 144(23):1831-1841. PubMed ID: 34637332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    Krantz MJ; Debus SE; Hsia J; Patel MR; Anand SS; Nehler MR; Hess CN; Capell WH; Bracken T; Szarek M; Mátyás L; Krievins DK; Nault P; Stefanov S; Haskell LP; Berkowitz SD; Muehlhofer E; Hiatt WR; Bauersachs RM; Bonaca MP
    Eur Heart J; 2021 Oct; 42(39):4040-4048. PubMed ID: 34430972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
    Bonaca MP; Szarek M; Debus ES; Nehler MR; Patel MR; Anand SS; Muehlhofer E; Berkowitz SD; Haskell LP; Bauersachs RM
    Clin Cardiol; 2022 Dec; 45(12):1143-1146. PubMed ID: 36251249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
    Hess CN; Patel MR; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Fanelli F; Yeh RW; Secemsky EA; Beckman JA; Mauri L; Govsyeyev N; Capell WH; Brackin T; Berkowitz SD; Muehlhofer E; Haskell LP; Hiatt WR; Bonaca MP
    J Am Coll Cardiol; 2021 Nov; 78(18):1768-1778. PubMed ID: 34711335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
    Hess CN; Szarek M; Anand SS; Bauersachs RM; Patel MR; Debus ES; Nehler MR; Capell WH; Beckman JA; Piazza G; Henkin S; Bura-Rivière A; Lawall H; Roztocil K; Hsia J; Muehlhofer E; Berkowitz SD; Haskell LP; Bonaca MP
    JAMA Netw Open; 2022 Jun; 5(6):e2215580. PubMed ID: 35731517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
    Berkowitz SD; Bauersachs RM; Szarek M; Nehler MR; Debus ES; Patel MR; Anand SS; Capell WH; Hess CN; Hsia J; Leeper NJ; Brasil D; Mátyás L; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Bonaca MP
    J Thromb Haemost; 2022 May; 20(5):1193-1205. PubMed ID: 35170216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
    Yuan Z; Levitan B; Deng H; Szarek M; Bauersachs RM; Berkowitz SD; Haskell L; Barnathan ES; Bonaca MP
    J Am Heart Assoc; 2024 Apr; 13(8):e032782. PubMed ID: 38563380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison with the Voyager Pad Endovascular Cohort.
    Czihal M; Malyar N; Stausberg J; Hoffmann U;
    J Cardiovasc Dev Dis; 2023 Mar; 10(3):. PubMed ID: 36975879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.